Analyst Expectations for Alnylam Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received 19 analyst ratings in the last quarter, with an average price target of $246.53, representing an upside from the current price of $177.3. The ratings are predominantly bullish, with 8 bullish, 6 somewhat bullish, and 5 indifferent ratings. The current average price target has decreased slightly by 0.99% from the previous target of $249.00. Analysts typically review stocks each quarter and their ratings are based on company performance, financial analysis, and market conditions.
December 08, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has a strong analyst backing with 19 ratings skewing towards bullish over the last quarter. The average price target suggests a significant upside potential from the current trading price.
The predominance of bullish ratings and the average price target above the current stock price suggest that analysts expect the stock to perform well in the short term. The slight decrease in the average price target may be a minor concern, but the overall positive sentiment is likely to have a favorable impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100